Related Experiment Video
Updated: May 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
1Division of Urologic Surgery, Washington University in Saint Louis, St. Louis, MO, USA, andrioleg@wustl.edu.
Abstract:
The prostate portion of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial began in the early 1990s to assess the ability of annual PSA and DRE to reduce prostate cancer specific mortality in men aged 55-74. Approximately 80,000 men have been randomized and followed for a minimum of 13 years. Thus far, annual screening in this study has not been associated with a reduction of prostate cancer specific mortality. The potential explanations for this finding are reviewed.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Clinical Trials: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Clinical Trials
There are four phases in a clinical trial. A phase one...

